Onconetix, Inc. Common Stock (ONCO)
Onconetix, Inc. (ONCO) is a biotechnology company focused on the development of diagnostic and therapeutic solutions for cancer detection and treatment. The company specializes in leveraging advanced molecular and genomic technologies to improve the accuracy and effectiveness of cancer diagnostics, aiming to enhance personalized medicine and patient outcomes.
Company News
Onconetix and Ocuvex Therapeutics have signed a definitive merger agreement where Onconetix will acquire Ocuvex, with Ocuvex shareholders receiving 90% of the combined company's equity. The transaction is expected to close in Q4 and aims to bring ophthalmic therapeutic assets to the public markets.
Onconetix, Inc. announced the closing of the exercise of existing warrants and the issuance of new warrants in a private placement, raising approximately $1.11 million. The company plans to use the proceeds for working capital and general corporate purposes.